Search PubMed⌕ Search

Biomedical subjects

J Hecht

Publications and source records attributed to J Hecht.

43 records · Page 3Linked to original sources
PubMed1979

Teratogenic effect of cyclophosphamide and the preventive effects of pyrithinoldehydrochloride monohydrate.

Teratogenic effects were induced in outbred Swiss mice by treatment of 8-week-old pregnant females with one of five different doses (5, 10, 20, 30, 40 mg/kg b.w.) of cyclophosphamide. Because the 11.5th day of pregnancy was the most effective day to induce malformations in mice, animals treated on this day were used for prophylactic studies. A preliminary study had shown that 30 mg/kg b.w. cyclophosphamide was the ideal dose to produce 100% malformations on the 11.5th day of pregnancy. From day 7.5 to 9.5 all fetuses were resorbed with this dosage. Most malformations were induced with 20, 30 or 40 mg/kg b.w., whereas 5 and 10 mg/kg b.w. caused no alterations of the fetuses. The frequency distributions of the various induced malformations and combined malformations of a positive control group (30 mg/kg b.w. of cyclophosphamide on the 11.5th day of pregnancy) were compared to those found in groups receiving different doses of the prophylactic. This substance reduced significantly the rate of malformations; 1/160 LD50 pyrithinoldehydrochloride monohydrate administered 4 times prior to cyclophosphamide treatment was the most effective. However, a complete prevention of teratogenic effects could not be accomplished.

Abnormalities, Drug-Induced↗
PubMed1977

[Animal experimental studies on the prevention of cleft palate and other malformations in the region of the head].

In fetuses of eight-week old female Swiss mice, teratogenic effects were produced by cyclophosphamid on different days of pregnancy. Frequently and combinations of malformation of a positive control group (30 mg/kg b.w. on the 11.5th day of pregnancy) were compared with "prophylaxis" groups. Pyrithioxin (Encephabol) significantly reduces the number of some malformations. The goal, i.e. to obtain normal fetuses without malformations, was not achieved, however. The best effect was obtained with 1/160 LD50 of Encephabol administered in four doses prior to Endoxan.

Abnormalities, Multiple↗
PubMed1975

An accessory table for supine horizontal-beam polytome laminagraphy.

A two-part accessory table for use with the Philips Polytome is described. It permits brow-up lateral polytomography and submentovertex examinations to be carried out with the patient resting comfortably. Accuracy to 1 mm in positioning of the tomographic section is maintained.

Humans↗
PubMedDate not supplied

Characteristics of patients adhering to a hospital's no-smoking policy.

OBJECTIVES: The purpose of this paper is to examine the characteristics of smokers who adhere to a hospital smoking ban, compared to those who do not. DESIGN: The data presented in this paper are baseline and discharge survey data collected among hospitalized smokers. SETTING: This study was conducted in two teaching hospitals in a northeastern city. PATIENTS/PARTICIPANTS: The subjects were 358 smokers who participated in a larger smoking intervention trial. MAIN RESULTS: Seventy-six percent of the subjects reported adhering to the smoke-free policy during their hospital stay. In a multivariate model, demographic factors that predicted adherence included being older, having shorter length of stay, not reporting recreational drug use in the previous 12 months, and not having alcohol-related problems. Smoking history variables that predicted adherence included having had at least 24 h of abstinence in the 7 days prior to hospitalization; self-efficacy variables (e.g., confidence in ability to quit smoking in 1 month and less anticipated difficulty refraining from smoking during hospitalization) also predicted adherence. CONCLUSIONS: Understanding the factors that predict adherence to health care policies can provide useful information for health promotion interventions in a medical setting. The implications of these findings are discussed.

Age Factors↗
PubMedDate not supplied

Chronic care costs in managed care.

This DataWatch presents estimates of the health care costs for all adults who were continuously enrolled in a large staff-model health maintenance organization (HMO) during 1992. More than one-third of these adults were diagnosed with at least one chronic condition in 1992, and costs for this population are at least twice those of the population without chronic conditions. A diagnosis of a chronic condition results in an expected increase in costs of 80 percent-300 percent, depending on age, sex, and chronic condition profile. Previous studies of the costs of chronic illness have focused on the fee-for-service sector. As managed care continues to grow, it is important that economic analyses focus on this market segment.

Adult↗